March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Trabectome™ Outcomes in Patients of African Decent
Author Affiliations & Notes
  • Ninita H. Brown
    Ophthalmology, Howard University, Washington, Dist. of Columbia
  • Leslie S. Jones
    Ophthalmology, Howard University Hospital, Washington, Dist. of Columbia
  • Footnotes
    Commercial Relationships  Ninita H. Brown, None; Leslie S. Jones, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5929. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ninita H. Brown, Leslie S. Jones; Trabectome™ Outcomes in Patients of African Decent. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5929.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To present the outcomes in Trabectome™ alone versus Trabectome™ combined with phacoemulsification in patients of African decent.

Methods: : A prospective, non-randomized, observational, comparative cohort study of 142 patients of African descent who underwent Trabectome™ surgery from 2006 to 2011 in multiple centers. The patients are stratified into the 2 groups of Trabectome™ alone versus Trabectome™ combined with cataract extraction by phacoemulsification. Inclusion criteria were open-angle glaucoma patients with uncontrolled intraocular pressure on maximum tolerated medical therapy with a 12-month postoperative follow up. The outcome measures are intraocular pressure (IOP), the number of glaucoma medications, and the occurrence of any secondary surgeries.

Results: : All patients with Trabectome™ surgery included both alone or in combination with phacoemulsification (n=142) were evaluated at 12 months post-operatively. In the entire group, the IOP was reduced by 22%. The average preoperative and postoperative IOP decreased from 23.5±7.4 mmHg to 17.1±4.1 mmHg (p<0.01), respectively. The mean preoperative and postoperative number of glaucoma medication changed from 2.70±1.37 to 2.46±1.49 (p=0.32), respectively. Thus, the mean glaucoma medications were not statistically significantly reduced. In the subset of patients with Trabectome™ alone (n=82), the IOP was reduced by 28%. The average preoperative and postoperative IOP decreased from 26.3±7.1 mmHg to 17.9±4.6 mmHg (p<0.01), respectively. The mean preoperative and postoperative number of glaucoma medications changed from 3.09±1.32 to 3.04±1.08 (p=0.8), respectively. Thus, the mean glaucoma medications were not statistically significantly reduced. In the subset of patients with Trabectome™ combined with phacoemulsification (n=60), the IOP reduced by 15%. The average preoperative and postoperative IOP decreased from 9.6±6.1 mmHg to 16.1±3.2 mmHg (p<0.01), respectively. The mean preoperative and postoperative number of glaucoma medications changed from 2.17±1.28 to 1.83±1.63 (p=0.4), respectively. Thus, the mean glaucoma medications were not statistically significantly reduced. The percentages of secondary surgeries in the entire group, the Trabectome™ alone group, and the Trabectome™ combined with phacoemulsification group were 11%, 17%, and 3%, respectively (p<0.01).

Conclusions: : The decrease in IOP is significant in each of the groups. There is no significant decrease in the number of glaucoma medications. The lowest rate of secondary surgeries occurs in Trabectome™ combined with phacoemulsification.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×